John E J Rasko

List of Publications by Year in Descending Order

196 papers	11,420 citations	51 h-index	103 g-index
222 ext. papers	13,522 ext. citations	9.9 avg, IF	6.05 L-index

#	Paper	IF	Citations
196	The next wave of cellular immunotherapies in pancreatic cancer.. *Molecular Therapy - Oncolytics*, **2022**, 24, 561-576	6.4	4
195	Sprouty and Spred temporally regulate ERK1/2-signaling to suppress TGF□induced lens EMT.. *Experimental Eye Research*, **2022**, 109070	3.7	1
194	Dynamic intron retention modulates gene expression in the monocytic differentiation pathway. *Immunology*, **2021**,	7.8	1
193	Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. *New England Journal of Medicine*, **2021**, 385, 1961-1973	59.2	18
192	Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy. *Blood*, **2021**, 138, 3975-3975	2.2	4
191	Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease. *Frontiers in Immunology*, **2021**, 12, 761616	8.4	5
190	Structure-function relationships explain CTCF zinc finger mutation phenotypes in cancer. *Cellular and Molecular Life Sciences*, **2021**, 78, 7519-7536	10.3	4
189	CTCF as a regulator of alternative splicing: new tricks for an old player. *Nucleic Acids Research*, **2021**, 49, 7825-7838	20.1	8
188	Holding on to Junk Bonds: Intron Retention in Cancer and Therapy. *Cancer Research*, **2021**, 81, 779-789	10.1	5
187	Journey to the Center of the Cell: Tracing the Path of AAV Transduction. *Trends in Molecular Medicine*, **2021**, 27, 172-184	11.5	11
186	haploinsufficiency mediates intron retention in a tissue-specific manner. *RNA Biology*, **2021**, 18, 93-103	4.8	5
185	Anti-Mesothelin CAR T cell therapy for malignant mesothelioma. *Biomarker Research*, **2021**, 9, 11	8	13
184	Hitting the Bull□s-Eye: Mesothelin□s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma. *Cancers*, **2021**, 13,	6.6	1
183	Splice and Dice: Intronic microRNAs, Splicing and Cancer. *Biomedicines*, **2021**, 9,	4.8	2
182	Computational Methods for Intron Retention Identification and Quantification **2021**, 63-74		
181	Surveying brain tumor heterogeneity by single-cell RNA-sequencing of multi-sector biopsies. *National Science Review*, **2020**, 7, 1306-1318	10.8	15
180	Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial. *Clinical Cancer Research*, **2020**, 26, 4521-4530	12.9	9

179	Advances in targeted therapy for malignant lymphoma. *Signal Transduction and Targeted Therapy*, **2020**, 5, 15	21	26
178	Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B. *Molecular Therapy*, **2020**, 28, 2073-2082	11.7	49
177	Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. *Nature Communications*, **2020**, 11, 2042	17.4	50
176	Macrophage development and activation involve coordinated intron retention in key inflammatory regulators. *Nucleic Acids Research*, **2020**, 48, 6513-6529	20.1	15
175	The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. *Signal Transduction and Targeted Therapy*, **2020**, 5, 134	21	36
174	Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. *Nature Medicine*, **2020**, 26, 1720-1725	50.5	82
173	Global citizen deliberation on genome editing. *Science*, **2020**, 369, 1435-1437	33.3	27
172	Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients. *Cancers*, **2020**, 12,	6.6	3
171	Stem Cell Businesses and Right to Try Laws. *Cell Stem Cell*, **2019**, 25, 304-305	18	2
170	Exosomal lncRNAs and cancer: connecting the missing links. *Bioinformatics*, **2019**, 35, 352-360	7.2	39
169	EGF-activated PI3K/Akt signalling coordinates leucine uptake by regulating LAT3 expression in prostate cancer. *Cell Communication and Signaling*, **2019**, 17, 83	7.5	12
168	Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year. *Blood*, **2019**, 134, 3347-3347	2.2	11
167	Cell and gene therapy manufacturing capabilities in Australia and New Zealand. *Cytotherapy*, **2019**, 21, 1258-1273	4.8	3
166	The changing paradigm of intron retention: regulation, ramifications and recipes. *Nucleic Acids Research*, **2019**, 47, 11497-11513	20.1	41
165	The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy. *Frontiers in Oncology*, **2019**, 9, 1366	5.3	29
164	DNA methylation/hydroxymethylation regulate gene expression and alternative splicing during terminal granulopoiesis. *Epigenomics*, **2019**, 11, 95-109	4.4	11
163	Spred negatively regulates lens growth by modulating epithelial cell proliferation and fiber differentiation. *Experimental Eye Research*, **2019**, 178, 160-175	3.7	7
162	No Vacillation on HPV Vaccination. *Cell*, **2018**, 172, 1163-1167	56.2	14

161	Negative regulation of lens fiber cell differentiation by RTK antagonists Spry and Spred. *Experimental Eye Research*, **2018**, 170, 148-159	3.7	6
160	Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. *New England Journal of Medicine*, **2018**, 378, 1479-1493	59.2	347
159	An intriguing, new planarian species from Tasmania, with a discussion on protandry in triclad flatworms (Platyhelminthes, Tricladida). *Acta Zoologica*, **2018**, 99, 404-414	0.8	
158	We skip to work: alternative splicing in normal and malignant myelopoiesis. *Leukemia*, **2018**, 32, 1081-1092	10.7	23
157	Challenges in defining the role of intron retention in normal biology and disease. *Seminars in Cell and Developmental Biology*, **2018**, 75, 40-49	7.5	30
156	Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy. *Biochemical and Biophysical Research Communications*, **2018**, 503, 1861-1867	3.4	3
155	Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten. *Epigenetics and Chromatin*, **2018**, 11, 24	5.8	27
154	Identifying microRNA determinants of human myelopoiesis. *Scientific Reports*, **2018**, 8, 7264	4.9	8
153	A Phase I Trial of iPSC-Derived MSCs (CYP-001) in Steroid-Resistant Acute GvHD. *Blood*, **2018**, 132, 4562-4562	15.2	4
152	CTCF Expression is Essential for Somatic Cell Viability and Protection Against Cancer. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	11
151	Cell, tissue and gene products with marketing authorization in 2018 worldwide. *Cytotherapy*, **2018**, 20, 1401-1413	4.8	59
150	Nuclear microRNAs in normal hemopoiesis and cancer. *Journal of Hematology and Oncology*, **2017**, 10, 8	22.4	23
149	Genetic alterations of mA regulators predict poorer survival in acute myeloid leukemia. *Journal of Hematology and Oncology*, **2017**, 10, 39	22.4	145
148	Intron retention is regulated by altered MeCP2-mediated splicing factor recruitment. *Nature Communications*, **2017**, 8, 15134	17.4	63
147	Computational and Experimental Identification of Tissue-Specific MicroRNA Targets. *Methods in Molecular Biology*, **2017**, 1580, 127-147	1.4	6
146	The antiproliferative ELF2 isoform, ELF2B, induces apoptosis in vitro and perturbs early lymphocytic development in vivo. *Journal of Hematology and Oncology*, **2017**, 10, 75	22.4	9
145	CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic. *Oncogene*, **2017**, 36, 4100-4110	9.2	29
144	Show drugs work before selling them. *Nature*, **2017**, 543, 174-175	50.4	8

143	Implicit hype? Representations of platelet rich plasma in the news media. *PLoS ONE*, **2017**, 12, e0182496	3.7	38
142	Intron retention enhances gene regulatory complexity in vertebrates. *Genome Biology*, **2017**, 18, 216	18.3	44
141	Marketing of unproven stem cell-based interventions: A call to action. *Science Translational Medicine*, **2017**, 9,	17.5	104
140	ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma. *Oncogenesis*, **2017**, 6, e367	6.6	40
139	Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. *New England Journal of Medicine*, **2017**, 377, 2215-2227	59.2	378
138	IRFinder: assessing the impact of intron retention on mammalian gene expression. *Genome Biology*, **2017**, 18, 51	18.3	109
137	First Approved Kinase Inhibitor for AML. *Cell*, **2017**, 171, 981	56.2	8
136	ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. *Oncogene*, **2016**, 35, 3201-8	9.2	290
135	Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015. *Neuromuscular Disorders*, **2016**, 26, 462-71	2.9	2
134	RBM3 regulates temperature sensitive miR-142-5p and miR-143 (thermomiRs), which target immune genes and control fever. *Nucleic Acids Research*, **2016**, 44, 2888-97	20.1	34
133	Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical Study. *Blood*, **2016**, 128, 1175-1175	2.2	13
132	Science, ethics and communication remain essential for the success of cell-based therapies. *Brain Circulation*, **2016**, 2, 146-151	2.7	5
131	PtdIns(3,4,5)P3-dependent Rac Exchanger 1 (PREX1) Rac-Guanine Nucleotide Exchange Factor (GEF) Activity Promotes Breast Cancer Cell Proliferation and Tumor Growth via Activation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Signaling. *Journal of Biological Chemistry*, **2016**, 291, 17258-70	5.4	12
130	A dynamic intron retention program in the mammalian megakaryocyte and erythrocyte lineages. *Blood*, **2016**, 127, e24-e34	2.2	63
129	Part 2: Making the "unproven" "proven". *Cytotherapy*, **2016**, 18, 120-3	4.8	4
128	Experimental approaches to studying the nature and impact of splicing variation in zebrafish. *Methods in Cell Biology*, **2016**, 135, 259-88	1.8	2
127	LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma. *International Journal of Cancer*, **2016**, 139, 2529-39	7.5	28
126	Global Distribution of Businesses Marketing Stem Cell-Based Interventions. *Cell Stem Cell*, **2016**, 19, 158-162	18	96

125	Intron retention in mRNA: No longer nonsense: Known and putative roles of intron retention in normal and disease biology. *BioEssays*, **2016**, 38, 41-9	4.1	127
124	Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions. *Genome Biology*, **2015**, 16, 161	18.3	64
123	Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. *Journal of Pathology*, **2015**, 236, 278-89	9.4	208
122	A Dynamic Intron Retention Program in the Mammalian Megakaryocyte and Erythrocyte Lineages. *Blood*, **2015**, 126, 2380-2380	2.2	0
121	CTCF and BORIS in genome regulation and cancer. *Current Opinion in Genetics and Development*, **2014**, 24, 8-15	4.9	35
120	Clinical potential of gene therapy: towards meeting the demand. *Internal Medicine Journal*, **2014**, 44, 224-33	1.6	8
119	Monoterpene glycoside ESK246 from Pittosporum targets LAT3 amino acid transport and prostate cancer cell growth. *ACS Chemical Biology*, **2014**, 9, 1369-76	4.9	24
118	Identification of nuclear-enriched miRNAs during mouse granulopoiesis. *Journal of Hematology and Oncology*, **2014**, 7, 42	22.4	23
117	Inhibition of glutamine uptake regulates mTORC1, glutamine metabolism and cell growth in prostate cancer. *Cancer & Metabolism*, **2014**, 2, P27	5.4	78
116	Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer. *Cancer Letters*, **2014**, 346, 24-33	9.9	42
115	Refining microRNA target predictions: sorting the wheat from the chaff. *Biochemical and Biophysical Research Communications*, **2014**, 445, 780-4	3.4	29
114	Innovations: advances in cellular therapies relating to haematological conditions. *Pathology*, **2014**, 46, S31	1.6	
113	Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia. *Cancer Science*, **2014**, 105, 1457-63	6.9	15
112	Targeting glutamine transport to suppress melanoma cell growth. *International Journal of Cancer*, **2014**, 135, 1060-71	7.5	143
111	Small RNA changes en route to distinct cellular states of induced pluripotency. *Nature Communications*, **2014**, 5, 5522	17.4	43
110	Genome-wide characterization of the routes to pluripotency. *Nature*, **2014**, 516, 198-206	50.4	153
109	Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products. *Pathology*, **2014**, 46, 177-83	1.6	5
108	NMR q-space analysis of canonical shapes of human erythrocytes: stomatocytes, discocytes, spherocytes and echinocytes. *European Biophysics Journal*, **2013**, 42, 3-16	1.9	6

107	Orchestrated intron retention regulates normal granulocyte differentiation. *Cell*, **2013**, 154, 583-95	56.2	290
106	miREval 2.0: a web tool for simple microRNA prediction in genome sequences. *Bioinformatics*, **2013**, 29, 3225-6	7.2	33
105	MicroRNA target prediction and validation. *Advances in Experimental Medicine and Biology*, **2013**, 774, 39-53	3.6	46
104	Nichotherapy for stem cells: there goes the neighborhood. *BioEssays*, **2013**, 35, 183-90	4.1	13
103	MicroRNAs in myeloid malignancies. *British Journal of Haematology*, **2013**, 162, 162-76	4.5	33
102	The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells. *International Journal of Cancer*, **2013**, 133, 1603-13	7.5	37
101	Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. *Journal of the National Cancer Institute*, **2013**, 105, 1463-73	9.7	119
100	Androgen receptor and nutrient signaling pathways coordinate increased amino acid transport in prostate cancer progression. *BMC Proceedings*, **2012**, 6,	2.3	78
99	Integrated miRNA expression analysis and target prediction. *Methods in Molecular Biology*, **2012**, 822, 289-93	1.4	2
98	Defining and providing robust controls for microRNA prediction. *Bioinformatics*, **2012**, 28, 1058-61	7.2	28
97	New developments in cell and gene therapy. *Pathology*, **2012**, 44, S33-S34	1.6	
96	Intron Retention Coupled with Nonsense-Mediated Decay Determines Protein Expression and Nuclear Morphology in Granulopoiesis. *Blood*, **2012**, 120, 112-112	2.2	
95	Disambiguating epigenetics. *Pathology*, **2011**, 43, S35-S36	1.6	
94	OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. *Haematologica*, **2011**, 96, 213-20	6.6	12
93	Will cell reprogramming resolve the embryonic stem cell controversy? A narrative review. *Annals of Internal Medicine*, **2011**, 155, 114-21	8	14
92	Promises and challenges of stem cell research for regenerative medicine. *Annals of Internal Medicine*, **2011**, 155, 706-13, W217	8	14
91	Mobilisation strategies for normal and malignant cells. *Pathology*, **2011**, 43, 547-65	1.6	5
90	Cellular therapy in the Asia-Pacific region. A guide for the future pathologist. *Pathology*, **2011**, 43, 616-26	1.6	2

89	Gene therapy: therapeutic applications and relevance to pathology. *Pathology*, **2011**, 43, 642-56	1.6	10
88	How we mobilize haemopoietic stem cells. *Internal Medicine Journal*, **2011**, 41, 588-94	1.6	7
87	Impaired nutrient signaling and body weight control in a Na+ neutral amino acid cotransporter (Slc6a19)-deficient mouse. *Journal of Biological Chemistry*, **2011**, 286, 26638-51	5.4	57
86	Identification of P-Rex1 as a novel Rac1-guanine nucleotide exchange factor (GEF) that promotes actin remodeling and GLUT4 protein trafficking in adipocytes. *Journal of Biological Chemistry*, **2011**, 286, 43229-40	5.4	49
85	Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. *Cancer Research*, **2011**, 71, 7525-36	10.1	128
84	Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. *Journal of Clinical Investigation*, **2011**, 121, 446-53	15.9	98
83	A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. *Journal of Internal Medicine*, **2010**, 268, 286-95	10.8	65
82	Nuclear-localized tiny RNAs are associated with transcription initiation and splice sites in metazoans. *Nature Structural and Molecular Biology*, **2010**, 17, 1030-4	17.6	134
81	Substrate elasticity provides mechanical signals for the expansion of hemopoietic stem and progenitor cells. *Nature Biotechnology*, **2010**, 28, 1123-8	44.5	217
80	A gene therapy renaissance?. *Journal of Gastroenterology and Hepatology (Australia)*, **2010**, 25, 848-50	4	2
79	Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 22231-6	11.5	213
78	Autologous transplantation of endothelial progenitor cells genetically modified by adeno-associated viral vector delivering insulin-like growth factor-1 gene after myocardial infarction. *Human Gene Therapy*, **2010**, 21, 1327-34	4.8	33
77	Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. *Haematologica* , **2010**, 95, 1325-33	6.6	86
76	mimiRNA: a microRNA expression profiler and classification resource designed to identify functional correlations between microRNAs and their targets. *Bioinformatics*, **2010**, 26, 223-7	7.2	68
75	Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. *Molecular Cancer*, **2010**, 9, 299	42.1	70
74	Renal imino acid and glycine transport system ontogeny and involvement in developmental iminoglycinuria. *Biochemical Journal*, **2010**, 428, 397-407	3.8	48
73	Loss of solute carriers in T cell-mediated rejection in mouse and human kidneys: an active epithelial injury-repair response. *American Journal of Transplantation*, **2010**, 10, 2241-51	8.7	27
72	Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?. *Stem Cells*, **2010**, 28, 1686-702	5.8	48

71	Gene therapy for hemophilia: clinical trials and technical tribulations. *Seminars in Thrombosis and Hemostasis*, **2009**, 35, 81-92	5.3	27
70	Conserved expression patterns predict microRNA targets. *PLoS Computational Biology*, **2009**, 5, e1000513	5	43
69	Predicting microRNA targets and functions: traps for the unwary. *Nature Methods*, **2009**, 6, 397-8	21.6	136
68	A protein complex in the brush-border membrane explains a Hartnup disorder allele. *FASEB Journal* , **2008**, 22, 2880-7	0.9	150
67	MicroRNA in acute myeloid leukemia. *New England Journal of Medicine*, **2008**, 359, 653; author reply 653-4	59.2	2
66	Whither prometheusPliver? Greek myth and the science of regeneration. *Annals of Internal Medicine* , **2008**, 149, 421-6	8	22
65	Developing strategies for detection of gene doping. *Journal of Gene Medicine*, **2008**, 10, 3-20	3.5	44
64	Further evidence for allelic heterogeneity in Hartnup disorder. *Human Mutation*, **2008**, 29, 1217-21	4.7	25
63	Improved granulocyte colony-stimulating factor mobilization of hemopoietic progenitors using cytokine combinations in primates. *Stem Cells*, **2008**, 26, 2974-80	5.8	6
62	Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters. *Journal of Clinical Investigation*, **2008**, 118, 3881-92	15.9	80
61	Distribution of human endogenous retrovirus type W receptor in normal human villous placenta. *Pathology*, **2007**, 39, 406-12	1.6	22
60	Profound thrombocytopenia related to G-CSF. *American Journal of Hematology*, **2007**, 82, 229-30	7.1	19
59	Specific adeno-associated virus serotypes facilitate efficient gene transfer into human and non-human primate mesenchymal stromal cells. *Journal of Gene Medicine*, **2007**, 9, 22-32	3.5	13
58	CD8(+) T-cell responses to adeno-associated virus capsid in humans. *Nature Medicine*, **2007**, 13, 419-22	50.5	518
57	Duration of ERK1/2 phosphorylation induced by FGF or ocular media determines lens cell fate. *Differentiation*, **2007**, 75, 662-8	3.5	44
56	Persistence of the common Hartnup disease D173N allele in populations of European origin. *Annals of Human Genetics*, **2007**, 71, 755-61	2.2	12
55	Potential use of gene transfer in athletic performance enhancement. *Molecular Therapy*, **2007**, 15, 1751-66	11.7	47
54	Regulation of FcgammaR-stimulated phagocytosis by the 72-kDa inositol polyphosphate 5-phosphatase: SHIP1, but not the 72-kDa 5-phosphatase, regulates complement receptor 3 mediated phagocytosis by differential recruitment of these 5-phosphatases to the phagocytic cup. *Blood*, **2007**, 110, 4480-91	2.2	34

53	Autofluorescent proteins for flow cytometry. *Methods in Molecular Biology*, **2007**, 411, 99-110	1.4	1
52	Cell and gene therapy in Australia. *Cytotherapy*, **2007**, 9, 209-21	4.8	3
51	The use of retroviral vectors for gene transfer into hematopoietic stem cells. *Methods in Enzymology*, **2006**, 420, 82-100	1.7	1
50	Phosphatidylinositol 3-phosphate [PtdIns3P] is generated at the plasma membrane by an inositol polyphosphate 5-phosphatase: endogenous PtdIns3P can promote GLUT4 translocation to the plasma membrane. *Molecular and Cellular Biology*, **2006**, 26, 6065-81	4.8	52
49	Aqueous humour- and growth factor-induced lens cell proliferation is dependent on MAPK/ERK1/2 and Akt/PI3-K signalling. *Experimental Eye Research*, **2006**, 83, 667-78	3.7	48
48	Molecular insights from a novel cardiac troponin I mouse model of familial hypertrophic cardiomyopathy. *Journal of Molecular and Cellular Cardiology*, **2006**, 41, 623-32	5.8	29
47	Induced dystrophin exon skipping in human muscle explants. *Neuromuscular Disorders*, **2006**, 16, 583-90	2.9	60
46	Bill to ban reproduction of inmates with cancer proposed in New South Wales. *Medical Journal of Australia*, **2006**, 185, 575-6	4	1
45	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. *Nature Medicine*, **2006**, 12, 342-7	50.5	1525
44	The molecular basis of neutral aminoacidurias. *Pflugers Archiv European Journal of Physiology*, **2006**, 451, 511-7	4.6	48
43	AAV-2 Capsid-Specific CD8+ T Cells Limit the Duration of Gene Therapy in Humans and Cross-React with AAV-8 Capsid.. *Blood*, **2006**, 108, 455-455	2.2	2
42	Damage to incisors after nonmyeloablative total body irradiation may complicate NOD/SCID models of hemopoietic stem cell transplantation. *Comparative Medicine*, **2006**, 56, 209-14	1.6	7
41	Interleukin-10 regulates arterial pressure in early primate pregnancy. *Cytokine*, **2005**, 29, 176-85	4	33
40	Lymphoproliferative disorders: prospects for gene therapy. *Pathology*, **2005**, 37, 523-33	1.6	3
39	Neutral amino acid transport in epithelial cells and its malfunction in Hartnup disorder. *Biochemical Society Transactions*, **2005**, 33, 233-6	5.1	38
38	Characterization of mouse amino acid transporter B0AT1 (slc6a19). *Biochemical Journal*, **2005**, 389, 745-51	5.8	118
37	PCR-based expression analysis and identification of microRNAs. *Journal of Rnai and Gene Silencing*, **2005**, 1, 44-9		17
36	Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. *Nature Genetics*, **2004**, 36, 1003-7	36.3	209

35	Synthetic elastin hydrogels derived from massive elastic assemblies of self-organized human protein monomers. *Biomaterials*, **2004**, 25, 4921-7	15.6	211
34	Stem cell therapy of the liver--fusion or fiction?. *Liver Transplantation*, **2004**, 10, 471-9	4.5	33
33	Biodistribution of the RD114/mammalian type D retrovirus receptor, RDR. *Journal of Gene Medicine* , **2004**, 6, 249-59	3.5	36
32	The biology of CD45 and its use as a therapeutic target. *Leukemia and Lymphoma*, **2004**, 45, 229-36	1.9	46
31	Dynamic association of the mammalian insulator protein CTCF with centrosomes and the midbody. *Experimental Cell Research*, **2004**, 294, 86-93	4.2	32
30	Molecular cloning of mouse amino acid transport system B0, a neutral amino acid transporter related to Hartnup disorder. *Journal of Biological Chemistry*, **2004**, 279, 24467-76	5.4	193
29	Transdifferentiation: an attractive concept in search of evidence. *Pathology*, **2003**, 35, 5	1.6	1
28	Sensitive flow cytometric analysis reveals a novel type of parent-of-origin effect in the mouse genome. *Current Biology*, **2003**, 13, 955-9	6.3	31
27	A sensitive dual-fluorescence reporter system enables positive selection of ras suppressors by suppression of ras-induced apoptosis. *Cancer Gene Therapy*, **2003**, 10, 745-54	5.4	6
26	Transdifferentiation: an attractive concept in search of evidence. *Pathology*, **2003**, 35, 5	1.6	4
25	Hartnup disorder: polymorphisms identified in the neutral amino acid transporter SLC1A5. *Journal of Inherited Metabolic Disease*, **2002**, 25, 437-48	5.4	15
24	Rapid screening for high-titer retroviral packaging cell lines using an in situ fluorescence assay. *Human Gene Therapy*, **2002**, 13, 1005-13	4.8	8
23	BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 6806-11	11.5	279
22	Ex vivo selection for oncoretrovirally transduced green fluorescent protein-expressing CD34-enriched cells increases short-term engraftment of transduced cells in baboons. *Human Gene Therapy*, **2002**, 13, 891-9	4.8	11
21	Sustained multilineage gene persistence and expression in dogs transplanted with CD34(+) marrow cells transduced by RD114-pseudotype oncoretrovirus vectors. *Blood*, **2001**, 98, 2065-70	2.2	70
20	ZNF265--a novel spliceosomal protein able to induce alternative splicing. *Journal of Cell Biology*, **2001**, 154, 25-32	7.3	57
19	Is inheritable genetic modification the new dividing line? **2001**, 1-16		1
18	The science of inheritable genetic modification **2001**, 17-34		1

17	Reporters of gene expression: autofluorescent proteins. *Current Protocols in Cytometry*, **2001**, Chapter 9, Unit 9.12	3.6	1
16	Precise gene localization by phenotypic assay of radiation hybrid cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 7388-92	11.5	9
15	A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: possible role in G protein-coupled signal transduction. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 1385-90	11.5	188
14	The RD114/simian type D retrovirus receptor is a neutral amino acid transporter. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 2129-34	11.5	189
13	The thrombopoietic factor, Mpl-ligand. *International Journal of Biochemistry and Cell Biology*, **1998**, 30, 657-60	5.6	1
12	Improved Gene Transfer Into Baboon Marrow Repopulating Cells Using Recombinant Human Fibronectin Fragment CH-296 in Combination With Interleukin-6, Stem Cell Factor, FLT-3 Ligand, and Megakaryocyte Growth and Development Factor. *Blood*, **1998**, 92, 1878-1886	2.2	234
11	Retrovirus packaging cells expressing the Mus dunni endogenous virus envelope facilitate transduction of CHO and primary hematopoietic cells. *Journal of Virology*, **1998**, 72, 10242-5	6.6	9
10	Improved Gene Transfer Into Baboon Marrow Repopulating Cells Using Recombinant Human Fibronectin Fragment CH-296 in Combination With Interleukin-6, Stem Cell Factor, FLT-3 Ligand, and Megakaryocyte Growth and Development Factor. *Blood*, **1998**, 92, 1878-1886	2.2	51
9	Establishment of multipotential and antigen presenting cell lines derived from myeloid leukemias in GM-CSF transgenic mice. *Leukemia*, **1997**, 11, 732-42	10.7	8
8	Mpl ligand (MGDF) alone and in combination with stem cell factor (SCF) promotes proliferation and survival of human megakaryocyte, erythroid and granulocyte/macrophage progenitors. *Stem Cells*, **1997**, 15, 33-42	5.8	37
7	Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. *British Journal of Haematology*, **1997**, 97, 871-80	4.5	60
6	Cytokine Receptor Expression on Hematopoietic Stem and Progenitor Cells. *Blood*, **1997**, 89, 65-71	2.2	14
5	Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. *Lancet, The*, **1996**, 348, 1279-81	40	198
4	Activation of the mitogen-activated protein kinase pathway induces transcription of the PAC-1 phosphatase gene. *Molecular and Cellular Biology*, **1996**, 16, 2913-21	4.8	70
3	Thymoma and agranulocytosis: two case reports and literature review. *British Journal of Haematology*, **1996**, 95, 52-6	4.5	41
2	Attenuated platelet sensitivity to collagen in patients with neurofibromatosis type 1. *British Journal of Haematology*, **1995**, 89, 582-8	4.5	15
1	Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome. *Medical Journal of Australia*, **1992**, 157, 192-3	4	18